---
title: "AIM ImmunoTech Inc. (AIM.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AIM.US.md"
symbol: "AIM.US"
name: "AIM ImmunoTech Inc."
industry: "Biotechnology"
datetime: "2026-05-19T09:48:36.775Z"
locales:
  - [en](https://longbridge.com/en/quote/AIM.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AIM.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AIM.US.md)
---

# AIM ImmunoTech Inc. (AIM.US)

## Company Overview

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company’s flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [aimimmuno.com](https://aimimmuno.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:14.000Z

**Overall: D (0.67)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 326 / 387 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -35.62% |  |
| Net Profit YoY | 12.70% |  |
| P/B Ratio | 1.56 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3324295.06 |  |
| Revenue | 94000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 1533.03% | A |
| Profit Margin | -14123.40% | E |
| Gross Margin | 81.82% | A |
| Revenue YoY | -35.62% | E |
| Net Profit YoY | 12.70% | C |
| Total Assets YoY | 37.40% | A |
| Net Assets YoY | 155.09% | A |
| Cash Flow Margin | 85.23% | C |
| OCF YoY | -35.62% | E |
| Turnover | 0.01 | E |
| Gearing Ratio | 75.25% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - AIM ImmunoTech Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-35.62%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "12.70%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.56",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "3324295.06",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "94000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "1533.03%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-14123.40%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "81.82%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-35.62%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "12.70%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "37.40%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "155.09%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "85.23%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-35.62%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "75.25%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.25 | 98/387 | - | - | - |
| PB | 1.56 | 148/387 | - | - | - |
| PS (TTM) | 35.36 | 223/387 | 55.07 | 37.61 | 28.79 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Vaxart (VXRT.US) | A | A | A | C | B | A |
| 05 | Spero Therap (SPRO.US) | A | A | B | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-10T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.41 |
| Highest Target | 10.00 |
| Lowest Target | 10.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/AIM.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/AIM.US/norm.md)
- [Related News](https://longbridge.com/en/quote/AIM.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/AIM.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**